FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381112863> ?p ?o ?g. }

• W4381112863 abstract "<h3>Introduction</h3> Filgotinib (FIL) is an oral, JAK1 preferential inhibitor approved for the treatment of UC. FIL 200 mg (FIL200) was effective in inducing and maintaining clinical remission vs placebo (PBO) and well tolerated in the phase 2b/3 SELECTION trial (NCT02914522). The efficacy and safety of continued FIL200 are being assessed in the continuing SELECTION long-term extension (LTE; NCT02914535) study. <h3>Methods</h3> In SELECTION, adults with moderately to severely active UC received induction (IND) FIL200, FIL 100 mg (FIL100) or PBO once daily for 11 weeks. Patients in clinical remission or with a Mayo Clinic Score (MCS) response at week 10 (responders) could enter the 47-week Maintenance (MNT) Study. SELECTIONLTE enrolled patients who completed IND and MNT (completers), patients who were not responders at IND week 10 (non-responders), and patients with disease worsening during MNT. This interim analysis of the LTE population assessed the efficacy and safety of open-label FIL200 through LTE week 144 in completers and LTE week 192 in non-responders, respectively, representing a total of 3.9 years of treatment each. Continuous measures of partial MCS (pMCS) and proportions of patients achieving the MCID in total IBDQ score (≥16-point increase vs baseline) were assessed without imputation (as observed). Safety was assessed by the exposure-adjusted incidence rate per 100 patient-years of exposure (PYE) for treatment-emergent adverse events (TEAEs) and TEAEs of interest. <h3>Results</h3> This analysis included 148 completers and 372 non-responders (IND FIL100, n=212; IND FIL200, n=160). Among completers, the reductions in mean pMCS in SELECTION over weeks 0–10 were maintained up to LTE week 144 (<b>figure 1</b>). In non-responders, mean pMCS decreased from LTE baseline to week 192. High proportions of completers (>90%) and non-responders (>60%) achieved the MCID in IBDQ score; proportions were maintained over time. Safety events were as expected among all patients treated with open-label FIL200 in the LTE study (total PYE=2055.5). <h3>Conclusions</h3> FIL200 was effective in maintaining symptomatic remission and health-related quality of life for up to ~4 years. No new safety signals were observed over ~4 years of treatment, and safety events were comparable with those seen in previous analyses." @default.
• W4381112863 created "2023-06-19" @default.
• W4381112863 creator A5010357543 @default.
• W4381112863 creator A5042884495 @default.
• W4381112863 creator A5044859429 @default.
• W4381112863 creator A5048464948 @default.
• W4381112863 creator A5058012401 @default.
• W4381112863 creator A5070160313 @default.
• W4381112863 creator A5071194126 @default.
• W4381112863 creator A5071801832 @default.
• W4381112863 creator A5077494133 @default.
• W4381112863 date "2023-06-01" @default.
• W4381112863 modified "2023-10-18" @default.
• W4381112863 title "O63 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitis" @default.
• W4381112863 doi "https://doi.org/10.1136/gutjnl-2023-bsg.62" @default.
• W4381112863 hasPublicationYear "2023" @default.
• W4381112863 type Work @default.
• W4381112863 citedByCount "0" @default.
• W4381112863 crossrefType "proceedings-article" @default.
• W4381112863 hasAuthorship W4381112863A5010357543 @default.
• W4381112863 hasAuthorship W4381112863A5042884495 @default.
• W4381112863 hasAuthorship W4381112863A5044859429 @default.
• W4381112863 hasAuthorship W4381112863A5048464948 @default.
• W4381112863 hasAuthorship W4381112863A5058012401 @default.
• W4381112863 hasAuthorship W4381112863A5070160313 @default.
• W4381112863 hasAuthorship W4381112863A5071194126 @default.
• W4381112863 hasAuthorship W4381112863A5071801832 @default.
• W4381112863 hasAuthorship W4381112863A5077494133 @default.
• W4381112863 hasConcept C120665830 @default.
• W4381112863 hasConcept C121332964 @default.
• W4381112863 hasConcept C126322002 @default.
• W4381112863 hasConcept C142724271 @default.
• W4381112863 hasConcept C197934379 @default.
• W4381112863 hasConcept C203092338 @default.
• W4381112863 hasConcept C204787440 @default.
• W4381112863 hasConcept C27081682 @default.
• W4381112863 hasConcept C2779134260 @default.
• W4381112863 hasConcept C2780479503 @default.
• W4381112863 hasConcept C2908647359 @default.
• W4381112863 hasConcept C535046627 @default.
• W4381112863 hasConcept C61511704 @default.
• W4381112863 hasConcept C61943457 @default.
• W4381112863 hasConcept C71924100 @default.
• W4381112863 hasConcept C99454951 @default.
• W4381112863 hasConceptScore W4381112863C120665830 @default.
• W4381112863 hasConceptScore W4381112863C121332964 @default.
• W4381112863 hasConceptScore W4381112863C126322002 @default.
• W4381112863 hasConceptScore W4381112863C142724271 @default.
• W4381112863 hasConceptScore W4381112863C197934379 @default.
• W4381112863 hasConceptScore W4381112863C203092338 @default.
• W4381112863 hasConceptScore W4381112863C204787440 @default.
• W4381112863 hasConceptScore W4381112863C27081682 @default.
• W4381112863 hasConceptScore W4381112863C2779134260 @default.
• W4381112863 hasConceptScore W4381112863C2780479503 @default.
• W4381112863 hasConceptScore W4381112863C2908647359 @default.
• W4381112863 hasConceptScore W4381112863C535046627 @default.
• W4381112863 hasConceptScore W4381112863C61511704 @default.
• W4381112863 hasConceptScore W4381112863C61943457 @default.
• W4381112863 hasConceptScore W4381112863C71924100 @default.
• W4381112863 hasConceptScore W4381112863C99454951 @default.
• W4381112863 hasLocation W43811128631 @default.
• W4381112863 hasOpenAccess W4381112863 @default.
• W4381112863 hasPrimaryLocation W43811128631 @default.
• W4381112863 hasRelatedWork W2062109784 @default.
• W4381112863 hasRelatedWork W2064879719 @default.
• W4381112863 hasRelatedWork W2085830368 @default.
• W4381112863 hasRelatedWork W2766008196 @default.
• W4381112863 hasRelatedWork W3155195005 @default.
• W4381112863 hasRelatedWork W3164040616 @default.
• W4381112863 hasRelatedWork W3172359983 @default.
• W4381112863 hasRelatedWork W3200621203 @default.
• W4381112863 hasRelatedWork W3212096909 @default.
• W4381112863 hasRelatedWork W4385766906 @default.
• W4381112863 isParatext "false" @default.
• W4381112863 isRetracted "false" @default.
• W4381112863 workType "article" @default.